At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML). 1 ...
Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study It will be important to confirm this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback